
# **BioMime Morph BGM**

## **Study Highlights**

The objective of the study is to evaluate safety and performance of the BioMime<sup>M</sup> Morph Sirolimus-Eluting Coronary Stent System in very long (length  $\leq$  56 mm) coronary lesions in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm in real-world settings

- Study Design
- Prospective, single-centre, observational, real-world, post-marketing surveillance study





Follow-up at 1-month, 6-month, 12-month, 24-month and 36month post-procedure

### Study Endpoints

#### **Safety Endpoints**

• Major adverse cardiac events at 1, 6, 12, 24 and 36 months

— Composite of cardiac death, myocardial infarction and ischemia-driven target lesion revascularization

• Stent thrombosis

#### **Performance Endpoints**

- Freedom of target lesion failure at 1, 6, 12, 24 and 36 months
- Target vessel failure at 1, 6, 12, 24 and 36 months
- Procedural success within 24 hours
- Device success

#### **\*** Reference:

 Clinical Trial Registry – India: CTRI/2017/03/008167 <u>http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=17116&EncHid=&userName=CTRI/2017/03/008167</u>.